Back Login to subscribe 🔔 Set Alert

RDY Dr. Reddy's Laboratories Limited American Depositary Shares

15 min delay

Loading...

Loading...

Loading...

Loading options…

CALLS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

PUTS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

Loading insider data…

Date	Headline	Sentiment
	Dr. Reddy's Launches Generic Semaglutide In Canada, Expands GLP-1 Push	90.1%
	Dr Reddy's Laboratories shares are trading lower after the company reported worse-than-expected Q4 financial results.	97.22%
	Dr Reddy's Laboratories Q4 EPS $0.03 Misses $0.09 Estimate, Sales $821.821M Miss $866.120M Estimate	96.55%
	Dr Reddy's Received Marketing Authorization For Generic Semaglutide Tablets In India For Treatment Of Type 2 Diabetes From Drugs Controller General Of India (DCGI)	93.85%
	Earnings Scheduled For May 12, 2026	91.94%